Migraine Clinical Trial
— ReMMi-DOfficial title:
A Randomized Double-blind, Parallel-Group, Virtual Study to Evaluate the Efficacy and Safety of Two Digital Therapeutics in Late Adolescents and Adults for the Prevention of Episodic Migraine
Verified date | May 2024 |
Source | Click Therapeutics, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Randomized study of two digital therapeutics for the prevention of episodic migraine
Status | Completed |
Enrollment | 558 |
Est. completion date | May 28, 2024 |
Est. primary completion date | May 17, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - A participant will be eligible for entry into the study if all of the following criteria are met: 1. Willing and able to provide written informed consent to participate in the study, attend study visits, and comply with study-related requirements and assessments. 2. Lives in the United States. 3. Adult or late adolescent, 18 years of age or older at the time of informed consent. 4. Fluent in written and spoken English, confirmed by ability to read and understand the informed consent form. 5. The following will be physician-reviewed: Participant has at least a 1-year history of migraine (with or without aura) consistent with a diagnosis according to the International Classification of Headache Disorders, 3rd Edition. 1. Age of onset of migraines prior to 50 years of age 2. Migraine attacks, on average, lasting 4-72 hours if untreated 3. Per participant report, 4-14 migraine days per month within the last 3 months prior to the Screening Visit (a month is defined as 28 days) 4. Four to fourteen migraine days during the run-in period 6. Is currently managing migraines with =1 prescription acute treatment and/or prescription first or second-line preventive medications, as assessed by a physician. 7. Is the sole user of an iPhone with an iPhone operating system (iOS) 14 or later or a smartphone with an Android operating system (OS) 11 or later and is willing to download and use the Study App required by the protocol. 8. Is willing and able to receive SMS text messages and push messages on their smartphone. 9. Is the owner of, and has regular access to, an email address. 10. Has regular access to the Internet via cellular data plan and/or wifi. Exclusion Criteria: - A participant will not be eligible for study entry if any of the following criteria are met: 1. History of basilar migraine or hemiplegic migraine. 2. Active chronic pain syndromes, such as fibromyalgia, chronic pelvic pain, or complex regional pain syndrome (CRPS). 3. Other pain syndromes (including trigeminal neuralgia), psychiatric conditions (such as major depressive episode, bipolar disorder, major depressive disorder, schizophrenia), dementia, or significant neurological disorders (other than migraine) that, in the Investigator's opinion, might interfere with study assessments. 4. History of, treatment for, or evidence of, alcohol or drug abuse within the past 12 months (48 weeks) or having met DSM-V criteria for any significant substance use disorder within the past 12 months (48 weeks) from the date of the screening visit. 5. History of use of analgesics (e.g., nonsteroidal anti-inflammatory drugs [NSAIDs] or acetaminophen, including opioids) or butalbital on = 15 days per month during the 3 months (12 weeks) prior to the Screening Visit or during the run-in period. 6. Currently taking a prescription anti-calcitonin gene-related peptide (CGRP) for either episodic or chronic migraine. 7. Post-traumatic headache, persistent post-traumatic headache, or post-concussion syndrome. 8. Other significant episodic or chronic medical condition(s) that in the opinion of the Investigator, may confound the interpretation of findings to inform PDT development. 9. Failure to adhere with or inability to complete Study App inputs and onboarding activities during the run-in period. Participants who are not adherent during the run-in period are not eligible for study entry. 10. Previous enrollment in any digital therapeutics pilot or pivotal study for a migraine indication. 11. Participation in any other investigational clinical study while participating in this clinical study. |
Country | Name | City | State |
---|---|---|---|
United States | Click Therapeutics | New York | New York |
Lead Sponsor | Collaborator |
---|---|
Click Therapeutics, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in MMD (monthly migraine days) | Change from baseline in the number of Monthly Migraine Days (MMD) at Week 12 of intervention | Baseline to Week 12 | |
Secondary | Proportion of Patients with Decrease in MMD | Proportion of participants who have at least a 50% reduction from baseline in the mean number of MMD at Week 12 | Baseline to Week 12 | |
Secondary | Decrease in MMD | Change from baseline in the number of MMD recorded over the previous 28 days at Week 4 and Week 8 | Baseline to Weeks 4 and 8 | |
Secondary | Decrease in MMD | Change from baseline in the mean number of MMD over 12 weeks | Baseline to Week 12 | |
Secondary | Change in average headache severity | Change in the average severity of headache from the run-in period to Weeks 9-12 assessed by Likert-type scale of 1-3 in severity | Run-in to Weeks 9-12 | |
Secondary | Change in MSQ | Change from baseline in the Migraine-Specific Quality-of-Life Questionnaire v2.1 (MSQ) at Week 4, Week 8, and Week 12 | Baseline to Weeks 4, 8 and 12 | |
Secondary | Change in MIDAS | Change from baseline in the Migraine Disability Assessment (MIDAS) at Week 4, Week 8, and Week 12 | Baseline to Weeks 4, 8, and 12 | |
Secondary | Change in frequency of Migraine Medications | Change in the frequency used of acute migraine medications from the run-in period to Weeks 9-12 | Run-in to Weeks 9-12 | |
Secondary | Change in dose of Migraine Medications | Change in the dose of acute migraine medications from the run-in period to Weeks 9-12 | Run-in to Weeks 9-12 | |
Secondary | Change in type of Migraine Medications | Change in the type of acute migraine medications from the run-in period to Weeks 9-12 | Run-in to Weeks 9-12 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05525611 -
Cabergoline as a Preventive Treatment for Chronic Migraine
|
N/A | |
Completed |
NCT06192173 -
Patent Foramen Ovale Closure in Migraine
|
||
Recruiting |
NCT03832998 -
Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine
|
Phase 3 | |
Enrolling by invitation |
NCT04196933 -
Analysis of Vestibular Compensation Following Clinical Intervention for Vestibular Schwannoma
|
N/A | |
Not yet recruiting |
NCT06428838 -
Eptinezumab as an Adjunct to Standard of Care for Migraine in an Acute Emergency Context
|
Phase 3 | |
Completed |
NCT06304675 -
Manageable Environmental Factors in Migraine
|
||
Completed |
NCT04084314 -
Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study
|
Phase 4 | |
Recruiting |
NCT05517200 -
Pilot Study for a Machine Learning Test for Migraine
|
||
Completed |
NCT04179474 -
Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine
|
Phase 1 | |
Recruiting |
NCT04603976 -
Registry for Migraine - Clinical Core
|
Phase 4 | |
Completed |
NCT03597529 -
CHOCOlate MeLatonin for AdolescenT MigrainE
|
Phase 2 | |
Completed |
NCT04197349 -
Safety, Tolerability and Pharmacokinetics of ALD1910 in Healthy Men and Woman
|
Phase 1 | |
Recruiting |
NCT05891808 -
miR-155 Expression in Episodic and Chronic Migraine
|
||
Active, not recruiting |
NCT05064371 -
Long-Term Extension Study With Eptinezumab as Preventive Treatment in Participants With Migraine in Japan
|
Phase 3 | |
Suspended |
NCT04069572 -
Vibratory Stimulation for the Treatment of Chronic Pain
|
N/A | |
Not yet recruiting |
NCT04859374 -
Chronic Pain and Conditioned Pain Modulation After on Line-behavioral Approach
|
N/A | |
Not yet recruiting |
NCT03083860 -
Evaluation of Migraine Management Mobile App Combined With Electrophysiological Measurements for Identification of Migraine Attack Risk and Beneficial Preventive Actions.
|
N/A | |
Completed |
NCT02905227 -
A Study of the Pulmonary Safety and Pharmacokinetics of Zolmitriptan Inhalation Powder
|
Phase 1 | |
Enrolling by invitation |
NCT02532023 -
The Combined Effects of omega3 Fatty Acids and Curcumin Supplementation on Inflammatory and Endothelial Factors in Migraine Patients
|
Phase 4 | |
Completed |
NCT02108678 -
One-Day Intervention for Depression and Impairment in Migraine Patients
|
N/A |